SG11201907583TA - Methods for treating complement-mediated diseases and disorders - Google Patents
Methods for treating complement-mediated diseases and disordersInfo
- Publication number
- SG11201907583TA SG11201907583TA SG11201907583TA SG11201907583TA SG11201907583TA SG 11201907583T A SG11201907583T A SG 11201907583TA SG 11201907583T A SG11201907583T A SG 11201907583TA SG 11201907583T A SG11201907583T A SG 11201907583TA SG 11201907583T A SG11201907583T A SG 11201907583TA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- international
- california
- individual
- south san
- Prior art date
Links
- 230000000295 complement effect Effects 0.000 title abstract 3
- 208000037765 diseases and disorders Diseases 0.000 title abstract 2
- 230000001404 mediated effect Effects 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000004913 activation Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Transplantation (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
ON O O (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 20 September 2018 (20.09.2018) WIPO I PCT mu °million °nolo olomollm olomunom oimIE (10) International Publication Number WO 2018/170145 Al (51) International Patent Classification: C07K 16/18 (2006.01) A61P 37/06 (2006.01) A61K 39/395 (2006.01) (21) International Application Number: PCT/US2018/022462 (22) International Filing Date: 14 March 2018 (14.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/471,190 14 March 2017 (14.03.2017) US 62/553,059 31 August 2017 (31.08.2017) US (71) Applicant: BIOVERATIV USA INC. [US/US]; 951 Gate- way Boulevard, South San Francisco, California 94080 (US). (72) Inventors: VAN VLASSELAER, Peter; 108 Crescent Avenue, Portola Valley, California 94028 (US). PAR- RY, Graham; 951 Gateway Boulevard, South San Fran- cisco, California 94080 (US). STAGLIANO, Nancy E.; 951 Gateway Boulevard, South San Francisco, California 94080 (US). PANICKER, Sandip; 951 Gateway Boule- vard, South San Francisco, California 94080 (US). (74) Agent: KIM, Ji-Eun et al.; Sterne, Kessler, Goldstein & Fox P.L.L.C., 1100 New York Avenue, NW, Washington, District of Columbia 20005 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a)) (54) Title: METHODS FOR TREATING COMPLEMENT-MEDIATED DISEASES AND DISORDERS (57) : The present disclosure provides methods of treating a complement-mediated disease or disorder in an individual, and methods of inhibiting activation of complement component C4 in an individual in need thereof. The methods comprise administering to the individual an anti-Cls antibody. The methods also comprise administering an anti-Cls antibody in a fixed dose, e.g., 5.5 g, 6.5 g, or 7.5 g. The methods also comprise administering an effective dose of an anti-Cls antibody to the individual to achieve a minimum serum level of anti-Cls antibody for therapeutic effect.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762471190P | 2017-03-14 | 2017-03-14 | |
| US201762553059P | 2017-08-31 | 2017-08-31 | |
| PCT/US2018/022462 WO2018170145A1 (en) | 2017-03-14 | 2018-03-14 | Methods for treating complement-mediated diseases and disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201907583TA true SG11201907583TA (en) | 2019-09-27 |
Family
ID=61873979
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201907583TA SG11201907583TA (en) | 2017-03-14 | 2018-03-14 | Methods for treating complement-mediated diseases and disorders |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20210115116A1 (en) |
| EP (1) | EP3596121A1 (en) |
| JP (3) | JP7293122B2 (en) |
| KR (1) | KR20190128676A (en) |
| CN (1) | CN110753701A (en) |
| AU (2) | AU2018236267B2 (en) |
| BR (1) | BR112019018950A2 (en) |
| CA (1) | CA3055781A1 (en) |
| CR (1) | CR20190468A (en) |
| IL (1) | IL269174A (en) |
| MX (2) | MX2019010994A (en) |
| SG (1) | SG11201907583TA (en) |
| TW (2) | TWI848905B (en) |
| WO (1) | WO2018170145A1 (en) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3722320A3 (en) | 2012-10-25 | 2020-12-30 | Bioverativ USA Inc. | Anti-complement c1s antibodies and uses thereof |
| GB2509260B (en) | 2012-11-02 | 2016-05-04 | True North Therapeutics Inc | Anti-complement C1s antibodies and uses thereof |
| HK1259251A1 (en) | 2015-04-06 | 2019-11-29 | Bioverativ Usa Inc. | Humanized anti-c1s antibodies and methods of use thereof |
| MY198182A (en) | 2016-10-12 | 2023-08-09 | Bioverativ Usa Inc | Anti-C1s Antibodies and Methods of use Thereof |
| CN119371526A (en) | 2018-12-13 | 2025-01-28 | 阿尔金克斯有限公司 | Antibodies against human complement factor C2b and methods of use |
| GB2584105B (en) * | 2019-05-21 | 2023-08-02 | Argenx Bvba | Methods of treating neuropathy |
| MX2022006334A (en) * | 2019-11-26 | 2022-06-22 | Omeros Corp | Methods for treating and/or preventing idiopathic pneumonia syndrome (ips) and/or capillary leak syndrome (cls) and/or engraftment syndrome (es) and/or fluid overload (fo) associated with hematopoietic stem cell transplant. |
| FI129383B (en) * | 2020-06-15 | 2022-01-31 | Faron Pharmaceuticals Oy | Stable anti-clever-1 antibody formulation |
| EP4193153A1 (en) | 2020-08-06 | 2023-06-14 | Bioverativ USA Inc. | Inflammatory cytokines and fatigue in subject with a complement mediated disease |
| WO2022212645A1 (en) | 2021-03-31 | 2022-10-06 | Bioverativ Usa Inc. | Reducing surgery-associated hemolysis in cold agglutinin disease patients |
| EP4340879A4 (en) | 2021-05-20 | 2025-03-26 | Dianthus Therapeutics OpCo, Inc. | C1S-BINDING ANTIBODIES AND USES THEREOF |
| EP4337332A2 (en) | 2021-07-13 | 2024-03-20 | Mabwell Therapeutics Inc. | Anti-c1s antibodies and uses thereof |
| CN114874329A (en) * | 2022-05-19 | 2022-08-09 | 江苏大学 | Complement activation C1s enzyme fluorescence detection kit, detection method and application |
| AU2023286689A1 (en) * | 2022-06-24 | 2025-02-06 | Bioverativ Usa Inc. | Methods for treating complement-mediated diseases |
| WO2024112734A1 (en) | 2022-11-21 | 2024-05-30 | Dianthus Therapeutics Opco, Inc. | Antibodies that bind to c1s and uses thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| JPH02500329A (en) | 1987-05-21 | 1990-02-08 | クリエイテイブ・バイオマリキユールズ・インコーポレーテツド | Targeted multifunctional protein |
| DE3920358A1 (en) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE |
| DE69233482T2 (en) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Method for reducing the immunogenicity of antibody variable domains |
| EP0605522B1 (en) | 1991-09-23 | 1999-06-23 | Medical Research Council | Methods for the production of humanized antibodies |
| EP0617706B1 (en) | 1991-11-25 | 2001-10-17 | Enzon, Inc. | Multivalent antigen-binding proteins |
| DE614989T1 (en) | 1993-02-17 | 1995-09-28 | Morphosys Proteinoptimierung | Method for in vivo selection of ligand binding proteins. |
| GB2509260B (en) * | 2012-11-02 | 2016-05-04 | True North Therapeutics Inc | Anti-complement C1s antibodies and uses thereof |
| WO2015084999A1 (en) * | 2013-12-06 | 2015-06-11 | True North Therapeutics, Inc. | Complement component biomarker assays |
-
2018
- 2018-03-14 CR CR20190468A patent/CR20190468A/en unknown
- 2018-03-14 TW TW107108658A patent/TWI848905B/en active
- 2018-03-14 MX MX2019010994A patent/MX2019010994A/en unknown
- 2018-03-14 TW TW113122096A patent/TW202513092A/en unknown
- 2018-03-14 KR KR1020197029545A patent/KR20190128676A/en active Pending
- 2018-03-14 CN CN201880029619.1A patent/CN110753701A/en active Pending
- 2018-03-14 EP EP18715381.2A patent/EP3596121A1/en active Pending
- 2018-03-14 SG SG11201907583TA patent/SG11201907583TA/en unknown
- 2018-03-14 CA CA3055781A patent/CA3055781A1/en active Pending
- 2018-03-14 JP JP2019550688A patent/JP7293122B2/en active Active
- 2018-03-14 US US16/494,267 patent/US20210115116A1/en not_active Abandoned
- 2018-03-14 BR BR112019018950A patent/BR112019018950A2/en unknown
- 2018-03-14 WO PCT/US2018/022462 patent/WO2018170145A1/en not_active Ceased
- 2018-03-14 AU AU2018236267A patent/AU2018236267B2/en active Active
-
2019
- 2019-09-08 IL IL26917419A patent/IL269174A/en unknown
- 2019-09-13 MX MX2025010483A patent/MX2025010483A/en unknown
-
2023
- 2023-03-01 JP JP2023030606A patent/JP2023071824A/en active Pending
-
2025
- 2025-01-31 JP JP2025014511A patent/JP2025072437A/en active Pending
- 2025-06-12 AU AU2025204392A patent/AU2025204392A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7293122B2 (en) | 2023-06-19 |
| CA3055781A1 (en) | 2018-09-20 |
| TW201842931A (en) | 2018-12-16 |
| EP3596121A1 (en) | 2020-01-22 |
| AU2025204392A1 (en) | 2025-07-03 |
| JP2025072437A (en) | 2025-05-09 |
| TW202513092A (en) | 2025-04-01 |
| AU2018236267A1 (en) | 2019-09-26 |
| MX2025010483A (en) | 2025-10-01 |
| WO2018170145A1 (en) | 2018-09-20 |
| BR112019018950A2 (en) | 2020-04-22 |
| CR20190468A (en) | 2019-12-17 |
| US20210115116A1 (en) | 2021-04-22 |
| KR20190128676A (en) | 2019-11-18 |
| MX2019010994A (en) | 2020-12-01 |
| CN110753701A (en) | 2020-02-04 |
| JP2020511469A (en) | 2020-04-16 |
| JP2023071824A (en) | 2023-05-23 |
| AU2018236267B2 (en) | 2025-03-13 |
| TWI848905B (en) | 2024-07-21 |
| IL269174A (en) | 2019-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201907583TA (en) | Methods for treating complement-mediated diseases and disorders | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201810423XA (en) | Pd-1 / pd-l1 inhibitors for cancer treatment | |
| SG11201908391XA (en) | Methods for modulating an immune response | |
| SG11201909960UA (en) | Methods for improving memory and cognition and for treating memory and cognitive disorders | |
| SG11201809336QA (en) | Anti-pd-l1 antibodies | |
| SG11201808125RA (en) | Methods for solid tumor treatment | |
| SG11201903012RA (en) | Anti-c1s antibodies and methods of use thereof | |
| SG11201809531SA (en) | BINDING MOLECULES SPECIFIC FOR FCγGAMMA RIIA AND USES THEREOF | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201907804QA (en) | Pharmaceutical composition comprising selexipag | |
| SG11201908238SA (en) | Anti-c5 antibodies and uses thereof | |
| SG11201810927QA (en) | Pd-l1-specific antibodies and methods of using the same | |
| SG11201808525UA (en) | Anti-complement factor bb antibodies and uses thereof | |
| SG11201810525XA (en) | Anti-gitr antibodies and uses thereof | |
| SG11201806342SA (en) | Glucagon and glp-1 co-agonists for the treatment of obesity | |
| SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
| SG11201804673WA (en) | Novel anti-claudin antibodies and methods of use | |
| SG11201909064RA (en) | Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer | |
| SG11201810801QA (en) | Brain delivery protein | |
| SG11201906987RA (en) | Combination of a ppar agonist with a fxr agonist | |
| SG11201807255YA (en) | Treatment of autoimmune diseases with combinations of rxr agonists and thyroid hormones | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same |